<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692484</url>
  </required_header>
  <id_info>
    <org_study_id>060629</org_study_id>
    <nct_id>NCT00692484</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics</brief_title>
  <official_title>Pilot Evaluation of the Effect of Application Procedure on the Antimicrobial Effects of an Aqueous CHG and a Traditional Iodophor Scrub Paint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareFusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareFusion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate effect of application procedure on efficacy of 2 antiseptics for cleaning skin prior&#xD;
      to surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the effect of application procedure on the antimicrobial properties of a new product&#xD;
      and a currently marketed product. Study will be conducted using methods dictated by the FDA.&#xD;
&#xD;
      Study uses topical sampling from the abdomen and groin on intact skin and evaluates the&#xD;
      germs. Effects of blotting versus not blotting will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3.0 log10 reduction in CFU/cm2 on inguinal sites, and 2.0 log10 reduction in CFU/cm2 on abdominal sites</measure>
    <time_frame>10 minutes and 6 hours after application of test solutions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of blotting versus not blotting</measure>
    <time_frame>Blotting and not blotting after 2 minute application with CHG and 5 minute application of iodophor</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine gluconate 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Povidone iodine scrub and paint</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate</intervention_name>
    <description>Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ChloraPrep AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone iodine</intervention_name>
    <description>Povidone iodine scrub and paint. Administer topically.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Betadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Free of dermatoses, cuts, lesions, or other skin disorders around test sites&#xD;
&#xD;
          -  must not have received topical or systemic antimicrobials, antibiotics, or steroids&#xD;
             for 7 days prior to testing and agree to abstain from these materials until completion&#xD;
             of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos,&#xD;
             or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds,&#xD;
             or sunbathing during the 7 day pre-test period or during the test period&#xD;
&#xD;
          -  exposure of the test sites to strong detergents, solvents, or other irritants during&#xD;
             the 7 day pre-test period or during the test period&#xD;
&#xD;
          -  use of systemic or topical antibiotic medications, steroid medications, or any other&#xD;
             product known to affect the normal microbial flora of the skin during the 7 day&#xD;
             pre-test period or during the test period&#xD;
&#xD;
          -  known allergy to latex (rubber), alcohols, inks, or tape adhesives, or to common&#xD;
             antibacterial agents found in soaps, lotions, or ointments, particularly chlorhexidine&#xD;
             gluconate and povidone iodine&#xD;
&#xD;
          -  active skin rashes or breaks in the skin of the test sites&#xD;
&#xD;
          -  currently active skin disease or inflammatory skin condition, including contact&#xD;
             dermatitis&#xD;
&#xD;
          -  showering or bathing within the 72 hour period prior to sampling&#xD;
&#xD;
          -  participation in a clinical study in the past 7 days or current participation in&#xD;
             another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl S Paulsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President and CEO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioScience Laboratories</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <disposition_first_submitted>February 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 22, 2013</disposition_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimicrobial</keyword>
  <keyword>Antisepsis</keyword>
  <keyword>Topical antisepsis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

